Barinthus Biotherapeutics (BRNS) Competitors $1.44 -0.09 (-5.88%) Closing price 07/30/2025 04:00 PM EasternExtended Trading$1.46 +0.02 (+1.04%) As of 07/30/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BRNS vs. UPXI, HRTX, GBIO, ACB, SCPH, EDIT, MREO, MNPR, LFCR, and SGMTShould you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Upexi (UPXI), Heron Therapeutics (HRTX), Generation Bio (GBIO), Aurora Cannabis (ACB), scPharmaceuticals (SCPH), Editas Medicine (EDIT), Mereo BioPharma Group (MREO), Monopar Therapeutics (MNPR), Lifecore Biomedical (LFCR), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical products" industry. Barinthus Biotherapeutics vs. Its Competitors Upexi Heron Therapeutics Generation Bio Aurora Cannabis scPharmaceuticals Editas Medicine Mereo BioPharma Group Monopar Therapeutics Lifecore Biomedical Sagimet Biosciences Barinthus Biotherapeutics (NASDAQ:BRNS) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability. Do analysts prefer BRNS or UPXI? Barinthus Biotherapeutics presently has a consensus target price of $6.25, suggesting a potential upside of 334.03%. Upexi has a consensus target price of $16.00, suggesting a potential upside of 227.20%. Given Barinthus Biotherapeutics' higher probable upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Upexi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Barinthus Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Upexi 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, BRNS or UPXI? Upexi has higher revenue and earnings than Barinthus Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBarinthus Biotherapeutics$14.97M3.88-$61.07M-$1.64-0.88Upexi$26M16.81-$23.66MN/AN/A Does the media refer more to BRNS or UPXI? In the previous week, Upexi had 15 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 16 mentions for Upexi and 1 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 1.87 beat Upexi's score of 1.28 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Barinthus Biotherapeutics Very Positive Upexi Positive Is BRNS or UPXI more profitable? Barinthus Biotherapeutics has a net margin of 0.00% compared to Upexi's net margin of -135.86%. Barinthus Biotherapeutics' return on equity of -46.43% beat Upexi's return on equity.Company Net Margins Return on Equity Return on Assets Barinthus BiotherapeuticsN/A -46.43% -38.50% Upexi -135.86%-535.19%-122.94% Which has more volatility & risk, BRNS or UPXI? Barinthus Biotherapeutics has a beta of -0.8, suggesting that its share price is 180% less volatile than the S&P 500. Comparatively, Upexi has a beta of -0.58, suggesting that its share price is 158% less volatile than the S&P 500. Do institutionals & insiders have more ownership in BRNS or UPXI? 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 5.7% of Upexi shares are owned by institutional investors. 10.7% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 31.6% of Upexi shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryBarinthus Biotherapeutics beats Upexi on 7 of the 13 factors compared between the two stocks. Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BRNS vs. The Competition Export to ExcelMetricBarinthus BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.72M$3.03B$5.63B$9.53BDividend YieldN/A2.39%4.71%4.04%P/E Ratio-0.8824.3630.2020.54Price / Sales3.88322.40455.8798.78Price / CashN/A42.5936.0158.40Price / Book0.458.278.345.74Net Income-$61.07M-$55.06M$3.25B$259.12M7 Day Performance-17.48%-3.45%-2.15%-2.68%1 Month Performance54.82%13.91%7.97%8.53%1 Year Performance-3.36%3.45%36.49%14.91% Barinthus Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BRNSBarinthus Biotherapeutics3.6237 of 5 stars$1.44-5.9%$6.25+334.0%-3.4%$61.72M$14.97M-0.88107Positive NewsUpcoming EarningsUPXIUpexi2.6786 of 5 stars$7.70-5.5%$16.00+107.8%-30.1%$291.98M$26M0.00130Positive NewsInsider TradeOptions VolumeGap DownHigh Trading VolumeHRTXHeron Therapeutics3.6238 of 5 stars$1.90-1.0%$5.00+163.2%-36.3%$289.86M$144.29M-31.67300News CoveragePositive NewsUpcoming EarningsGBIOGeneration Bio3.9899 of 5 stars$4.27+1.4%$80.00+1,773.5%-86.1%$286.26M$19.89M-3.95150News CoverageUpcoming EarningsHigh Trading VolumeACBAurora Cannabis0.2419 of 5 stars$5.05+7.4%N/A-23.0%$284.04M$343.29M45.911,130News CoverageUpcoming EarningsSCPHscPharmaceuticals4.3283 of 5 stars$5.38+4.9%$14.00+160.2%+8.7%$284.02M$41.98M-2.8230Positive NewsEDITEditas Medicine4.0244 of 5 stars$3.36+6.7%$4.70+39.9%-53.5%$281.28M$35.84M-1.11230News CoverageUpcoming EarningsMREOMereo BioPharma Group1.8031 of 5 stars$1.76+2.9%$7.20+309.1%-56.4%$279.84MN/A-25.1440Gap UpMNPRMonopar Therapeutics2.3887 of 5 stars$45.22-2.6%$60.00+32.7%+1,118.5%$276.75MN/A-12.9910LFCRLifecore Biomedical1.4408 of 5 stars$7.44-0.3%$8.00+7.5%+12.5%$275.50M$128.26M-5.13690SGMTSagimet Biosciences2.6161 of 5 stars$9.60+8.7%$26.60+177.1%+150.4%$270.86MN/A-5.458 Related Companies and Tools Related Companies UPXI Competitors HRTX Competitors GBIO Competitors ACB Competitors SCPH Competitors EDIT Competitors MREO Competitors MNPR Competitors LFCR Competitors SGMT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BRNS) was last updated on 7/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BRNS Stock Alerts